** Drug developer Wave Life Sciences' WVE.O shares down 12.4% at $5.69
** WVE posts Q1 revenue of $9.18 million, missing analysts' estimates of $12.23 million - data compiled by LSEG
** Reports Q1 net loss of $46.9 million, compared with a loss of $31.6 million a year ago
** Co says it has cash and cash equivalents of $243.1 million as of March 31, with runway expected into 2027
** Including session's moves, stock down 52.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.